Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Vaxil Bio Ltd.
  6. Summary
    VXL   CA92243L1076

VAXIL BIO LTD.

(VXL)
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Bourse De Toronto
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
0.07(c) 0.065(c) 0.065(c) 0.07(c) 0.065(c) Last
57 949 8 280 53 311 45 150 142 470 Volume
+7.69% -7.14% 0.00% +7.69% -7.14% Change
More quotes
Estimated financial data (e)
Sales 2019 - - -
Net income 2019 -1,15 M -0,90 M -0,90 M
Net cash position 2019 0,01 M 0,01 M 0,01 M
P/E ratio 2019 -2,70x
Yield 2019 -
Sales 2020 - - -
Net income 2020 -1,36 M -1,06 M -1,06 M
Net cash position 2020 1,50 M 1,18 M 1,18 M
P/E ratio 2020 -22,5x
Yield 2020 -
Capitalization 8,88 M 6,94 M 6,96 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees -
Free-Float 91,5%
More Financials
Company
Vaxil Bio Ltd., formerly Emerge Resources Corp., is an immune-oncology biotechnology company. The Company is engaged in research and development of ImMucin vaccine to treat cancer. The Company develops immunotherapies, including neoantigen peptide products, and antibodies to treat cancer and infectious diseases. The Company offers VaxHit platform, which allows for identification, isolation and production of specific... 
More about the company
All news about VAXIL BIO LTD.
08/30Vaxil Bio Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/04VAXIL BIO : Names Avnir as Interim Chief Executive as Goren Departs
MT
08/04Vaxil Bio Ltd. Appoints Yuval Avnir as Interim Chief Executive Officer
CI
08/04VAXIL BIO : Announces Changes to Senior Management and Provides Updates on Current Researc..
AQ
08/04Vaxil Bio Ltd. Announces Executive Changes
CI
05/31Vaxil Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
05/31UPDATE : Vaxil Down Near 5% as Provides Research and Development Update
MT
05/31VAXIL BIO : Provides Research and Development Update
AQ
05/05VAXIL BIO : Announces CEO Resignation
AQ
05/05David Goren Resigns as Chief Executive Officer of Vaxil Bio Ltd
CI
04/29Vaxil Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
04/29Vaxil Bio Ltd. Auditor Raises 'Going Concern' Doubt
CI
04/19VAXIL BIO LTD.(TSXV : VXL) dropped from S&P/TSX Venture Composite Index
CI
03/11VAXIL BIO : Announces 2021 research and development strategy and progress
PU
03/11VAXIL BIO : Outlines 2021 Research Goals; Working on Covid-19 Vaccine
MT
More news
News in other languages on VAXIL BIO LTD.

- No features available -

More news
Chart VAXIL BIO LTD.
Duration : Period :
Vaxil Bio Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXIL BIO LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Yuval Avnir Chief Executive Officer
Gadi Levin Chairman & Chief Financial Officer
Terry F. Plasse Chief Medical Officer
Ari S. Kellen Independent Director
Shawn Langer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VAXIL BIO LTD.-78.33%7
MODERNA, INC.305.22%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.41.30%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-9.18%28 939